Ink4c functions as a dedicated inhibitor of cyclin-Ddependent kinases. Loss of Ink4c predisposes mice to tumor development and, in a dose-dependent manner, complements the tumor-promoting effects of various oncogenes. We have now addressed whether Ink4c loss impacts B-cell tumor development in the El-Myc transgenic mouse, a model of human Burkitt lymphoma. Loss of one or both alleles did not influence the onset of lymphoma in El-Myc transgenics, and did not appreciably affect Myc's proliferative or apoptotic responses in precancerous B cells. Nevertheless, Ink4c loss modulated the effects of Myc-induced transformation by decreasing the frequency of Arf loss, an ordinarily common event in El-Myc-induced lymphomas.
Introduction
Progression through the first gap (G1) phase into the DNA replicative (S) phase of the cell cycle is regulated by two families of cyclin-dependent kinase inhibitory proteins (CKIs), the Cip/Kip and the Ink4 families (Sherr and Roberts, 1999) . By preventing the phosphorylation of the retinoblastoma family proteins (Rb, p107 and p130) by cyclin-D-cdk4/6 or cyclin-E/cdk2 complexes, these CKIs enforce transcriptional repression by E2F complexes, thereby preventing entry into the S-phase. Of the four Ink4 family members (p16 Ink4a , p15
Ink4b
, p18
Ink4c and p19 Ink4d ), the first three possess tumor suppressor activities in humans and mice (Franklin et al., 1998; Ruas and Peters, 1998; Latres et al., 2000; Krimpenfort et al., 2001; Sharpless et al., 2001) . Interestingly, the Ink4a locus encodes another tumor suppressor, p19
Arf (p14 ARF in humans), which shares exons 2 and 3 with p16
Ink4a but which is initiated from an alternative upstream exon (1b) and is translated in an alternative reading frame (Quelle et al., 1995) . Importantly, Arf functions are linked to the p53 tumor suppressor pathway, as Arf inactivates p53's endogenous inhibitor Mdm2 (Lowe and Sherr, 2003) . Co-deletion of Ink4a/Arf, and the closely linked Ink4b gene, is a frequent event in cancer, implying that the pRb and p53 tumor suppressor pathways are coordinately inactivated under these circumstances (Lowe and Sherr, 2003) .
Three members of the Myc oncogene family of transcription factors, c-Myc (hereafter denoted Myc), N-Myc and L-Myc, are overexpressed in many human malignancies, directly by chromosomal translocations or amplifications, or indirectly by deregulation of signal transduction pathways that induce or repress their transcription (Eisenman, 2001; Nilsson and Cleveland, 2003) . Myc overexpression accelerates cell cycle progression (Roussel et al., 1991) , and this occurs through their induction of D-type cyclins (Bouchard et al., 1999) and their partner Cdk4 (Hermeking et al., 2000) , as well as by repressing p21
Cip1 (Herold et al., 2002; Seoane et al., 2002; Wu et al., 2003), p27 Kip1 (Yang et al., 2001 ), p15
Ink4b Staller et al., 2001 ) and p18
Ink4c (Knoepfler et al., 2002) . However, in normal cells this proliferative response is counterbalanced by Myc's ability to provoke apoptosis (Askew et al., 1991; Evan et al., 1992; Eischen et al., 1999; Pelengaris et al., 2002; Nilsson and Cleveland, 2003) . Thus, oncogenesis also requires the inactivation of apoptotic checkpoints, and this occurs through direct mutations of the Myc gene (Hemann et al., 2005) , by disabling the Arf-p53 pathway (Eischen et al., 1999; Schmitt et al., 1999) , and by altering the expression of Bcl-2 family proteins (Eischen et al., 2001 (Eischen et al., , 2002 Pelengaris et al., 2002) .
The p18 Ink4c protein acts as a tumor suppressor in some cell contexts. For example, Ink4c-knockout mice develop pituitary adenomas with 100% penetrance and, with a lesser incidence, develop testicular tumors and B-cell lymphoma (Franklin et al., 1998; Latres et al., 2000) . Loss of Ink4c collaborates with the loss of p53 or Patched-1 in the induction of medulloblastoma (Uziel et al., 2005) and with p53 loss in hemangiosarcoma (Zindy et al., 2003; Damo et al., 2005) . Mice lacking Ink4c also developed numerous malignancies following treatment with chemical carcinogens (Bai et al., 2003) . Finally, silencing of INK4C/CDKN2C expression was found in a subset of childhood medulloblastoma (Uziel et al., 2005) and is associated with poor prognosis in patients with Hodgkin's B-cell lymphoma and hepatocellular carcinoma (Morishita et al., 2004; Sanchez-Aguilera et al., 2004) . These clinical observations, together with the essential role of p18
Ink4c in plasma cell development (Morse et al., 1997; Tourigny et al., 2002) , suggested that loss of p18
Ink4c might affect the development of B-cell lymphomas. To address this issue, we used the Em-Myc transgenic mouse, a model of human Burkitt lymphoma, which overexpresses c-Myc in B cells by virtue of the immunoglobulin heavy-chain enhancer (Em) (Adams et al., 1985) . Em-Myc mice undergo a rather protracted course of disease that is associated with increased rates of B-cell proliferation that are initially offset by high rates of apoptosis. However, with time, pathways provoking apoptosis are disabled (Eischen et al., 1999; Schmitt et al., 1999) and these transgenics develop lethal, clonal lymphomas that are phenotypically similar to Burkitt lymphoma (Dalla-Favera et al., 1982) and mouse plasmacytoma (Crews et al., 1982) . Here, we report that Ink4c does not behave as a tumor suppressor that harnesses lymphoma development in Em-Myc transgenic mice. Nonetheless, nearly all lymphomas arising in EmMyc;Ink4c À/À mice lack bi-allelic deletions in the Ink4a/ Arf locus, that represent a hallmark of many tumors. Therefore, p18
Ink4c does not collaborate with Myc in Bcell transformation but acts as a modifier by affecting the selection for Arf loss.
Results

p18
Ink4c expression is sustained in Em-Myc lymphomas Myc suppresses the expression of several CKIs, including p27 Kip1 , p21
Cip1
, p15
Ink4b and p18 Ink4c (Seoane et al., , 2002 Staller et al., 2001; Yang et al., 2001; Herold et al., 2002; Knoepfler et al., 2002; Wu et al., 2003) . To investigate potential links between Myc and p18 Ink4c , we initially used Affymetrix gene chip microarray analysis and compared the expression of Ink4c to that of other Ink4 family members, CKIs, Cdk4 and Cdk6 in B220 þ splenocytes isolated from wild-type and precancerous Em-Myc transgenic littermates ( Figure 1a ). As expected, Cdk4 (a known Myc target (Hermeking et al., 2000) ) was elevated in precancerous (4-to 6-week-old) splenic B cells from Em-Myc mice, whereas these cells expressed reduced levels of Cdkn1b (encoding p27
Kip1
). By contrast, Ink4c (Cdkn2c) expression was induced in Em-Myc B cells (Po0.05), and there were no significant changes in the expression of Ink4a (Cdkn2a) or Ink4d (Cdkn2d). To confirm these analyses, transcript levels in both wildtype and precancerous Em-Myc bone marrow-and spleen-derived B220 þ cells were evaluated using quantitative real-time reverse transcriptase-polymerase chain reaction (PCR). Again, Cdkn1b expression was repressed in Em-Myc B cells, whereas Ink4c expression was significantly increased in splenic B cells from EmMyc mice ( Figure 1b ). However, these changes were not detectable in bone marrow-derived B cells, where levels of Ink4c expression were similar in wild-type and EmMyc B cells (Figure 1b) . Therefore, Myc induces, rather than represses, Ink4c expression in B cells in vivo.
Silencing and/or loss of some CKIs occur during malignant progression. We therefore assessed the levels of Ink4c transcripts and p18
Ink4c protein in tumors arising in Em-Myc mice and compared these to those expressed in B cells from wild-type and precancerous Em-Myc littermates. Levels of Ink4c transcripts were higher in most tumors than in normal B cells ( Figure 2a ) and approximately half of the lymphomas analysed expressed p18
Ink4c at levels comparable to those in precancerous Em-Myc B cells ( Figure 2b and data not mice. These mice were monitored for lymphoma development and the time of onset was plotted against the percentage of animals still alive (Figure 3a) . Although Em-Myc;Ink4c þ / þ littermates succumbed to disease somewhat later than their Em-Myc;Ink4c þ /À and Em-Myc;Ink4c À/À littermates, these differences were not statistically significant. Therefore, p18
Ink4c does not function as a tumor suppressor that limits Myc-induced lymphomagenesis in mice.
Em-Myc lymphomas are preceded by a protracted precancerous stage where hyperproliferation induced by Myc is counterbalanced by apoptosis (Jacobsen et al., 1994; Eischen et al., 1999; Baudino et al., 2003; Nilsson et al., 2005) . We reasoned that removing p18
Ink4c might Ink4c in Myc-induced transformation LM Nilsson et al be counterbalanced by increased apoptosis in EmMyc;Ink4c À/À B cells, which would cancel effects of Ink4c loss on Myc-induced proliferation and lymphomagenesis. We therefore analysed the proliferative and apoptotic indices of B cells from 6-week-old Em-Myc;Ink4c þ / þ and Em-Myc;Ink4c À/À littermates. To assess proliferative rates, these mice were injected with 5-bromodeoxyuridine (BrdU), and after 12 h cell suspensions were prepared from spleens and bone marrow, and the percentages of B cells in the S phase were determined by fluorescence-activated cell sorter (FACS). As expected , both surface immunoglobulin M (sIgM)-positive and sIgM-negative Em-Myc splenocytes had much higher numbers of cells in the S phase than B cells from wild-type mice (Figure 3b ). IgM þ B cells from the bone marrow of Em-Myc mice also exhibited a higher apoptotic index, as judged by increased numbers of Annexin-V þ cells (Figure 3c ). Notably, Ink4c loss had virtually no effect on the proliferative or apoptotic rates of precancerous Em-Myc B cells (Figure 3b and c) . Thus, Ink4c loss did not affect Myc-induced proliferation, apoptosis or tumorigenesis.
Loss of Ink4c biases against Arf loss in Myc-induced lymphomagenesis Southern blot analyses of tumors arising in Em-
Myc;Ink4c
þ /À mice revealed a high frequency (10/24) of lymphomas that had undergone loss of heterozygosity (LOH) at the Ink4c locus (Figure 4a ). However, among these 10 lymphomas, three lost the mutant, targeted Ink4c allele (L m ) (Figure 4b , second cohort), whereas seven had lost the wild-type Ink4c allele (L w ) (Figure 4a , first and second cohorts). In the mouse, the Ink4c locus resides on chromosome 4 and is genetically linked to the Ink4a/Arf locus, which is frequently deleted and undergoes LOH in Em-Myc tumors (Figure 4b ) (Eischen et al., 1999) . To elucidate if LOH of the Ink4c locus in Em-Myc;Ink4c þ /À tumors was mediated by gene conversion and bi-allelic Arf deletion, we analysed these tumors for the presence of the Arf gene by Southern blot (Figure 4a) . Three of three lymphomas that had undergone Ink4c LOH had also lost Arf (denoted by *, Figure 4a ) and others exhibited low levels of Arf protein, implicating that the Arf locus was affected (Figure 4a and data not shown). Comparative genomic hybridization (CGH) on these tumors did not reveal loss of the entire chromosome, suggesting that the loss of Arf is mediated by a smaller deletion in the locus and that the LOH of Ink4c and Arf is mediated by gene conversion (negative data not shown).
At least one-quarter of lymphomas arising in Em-Myc transgenic mice suffer bi-allelic deletions in Arf (Eischen et al., 1999) . In this cohort of Em-Myc mice, we observed bi-allelic Arf deletions in 41% (7/17) of Em-Myc;Ink4c (Figure 4a ). Therefore, loss of both Ink4c alleles biases against events that induce the loss of Arf. We also evaluated possible compensation by other Ink4 family members. In tumors from Em-Myc;Ink4c
Ink4a protein levels were undetectable, whereas p15
Ink4b was expressed in these tumors at the same level as lymphomas carrying Ink4c alleles (data not shown). Therefore, there is no apparent compensation by p16 Ink4a or p15
Ink4b for Ink4c loss.
Discussion
Disabling apoptotic or cell cycle checkpoints induced by the loss of Arf, p53 or p27
Kip1
, dramatically accelerates the course of lymphoma development in Em-Myc Ink4c in Myc-induced transformation LM Nilsson et al transgenic mice . Here, we interrogated the role of the Ink4 family member p18
Ink4c
in Em-Myc-induced B-cell lymphomas, especially given that loss or haploinsufficiency of Ink4c supports its role as a tumor suppressor, and because Ink4c-deficient mice resemble, in many respects, Kip1-deficient animals (Fero et al., 1996; Kiyokawa et al., 1996; Franklin et al., 1998; Latres et al., 2000) . Several pieces of evidence implicate p18 Ink4c as a tumor suppressor in B cells. p18
Ink4c function is required for proper plasma cell differentiation (Morse et al., 1997; Tourigny et al., 2002) and Ink4c-deficient mice develop late onset B-and T-cell lymphomas, albeit at a very low frequency (Franklin et al., 1998; Latres et al., 2000) . In addition, the putative cell-of-origin for Hodgkin's B-cell lymphoma, the Reed-Sternberg cells, frequently silence INK4C/CDKN2C gene expression by hypermethylation of its promoter, and this event connotes poor prognosis (Sanchez-Aguilera et al., 2004) . Finally, CDKN2C, is frequently deleted (38%) in primary human tumors and cell lines from multiple myeloma (Kulkarni et al., 2002) . Thus, we fully expected that Ink4c haploinsufficiency and/or loss would have profound effects on Mycinduced B-cell lymphomagenesis.
Our findings demonstrate that p18 Ink4c is not suppressed by Myc in precancerous B cells, a fact that clearly distinguishes this CKI from p27 Kip1 and p21
Cip1 , which are repressed by Myc (Vlach et al., 1996; Wu and Levine, 1997; Yang et al., 2001; Herold et al., 2002; Baudino et al., 2003) . Indeed, Ink4c expression was rather elevated in splenic Em-Myc B cells and its expression was sustained in many Em-Myc tumors and most human Burkitt lymphoma. These results suggest that Ink4c may be ineffective in preventing cell cycle progression in Myc-expressing cells, and that the observed increases in Ink4c in Myc-expressing B cells may reflect a futile response in attempts to restore cell cycle control. Our data are similar to those showing that Ink4a loss does not collaborate with Myc in B-cell lymphomagenesis (Krimpenfort et al., 2001) .
Analyses of lymphomas arising in Em-Myc;Ink4c þ /À mice showed frequent LOH, even though there were no effects of Ink4c heterozygosity (or Ink4c loss) on lymphoma development (Figure 1 ). LOH included events that led to loss of the mutant, targeted allele in the tumors, suggesting another important contributing locus in the vicinity of Ink4c. In the mouse genome, three out of four Ink4 genes, Ink4a-c, reside on chromosome 4, with a distance of B20 Mb separating Ink4c from the other Ink4 genes (Figure 4b ). The observation that Ink4c LOH occurred in lymphomas that also underwent bi-allelic deletion of Arf, suggested that gene conversion leading to complete Arf loss might encompass a large fragment of chromosome 4, of at least 20 Mb. The other alternative would be that the observed loss of the other allele (wild-type in the case of Arf, but either allele in the case of Ink4c) had occurred by chromosome loss. However, CGH analysis ruled out such an event. Nevertheless, the frequent LOH for Ink4c is in stark contrast to a previous study of carcinogeninduced cancer, where the Ink4c gene is haploinsufficient for tumor suppression in liver hemangiosarcomas (Bai et al., 2003) , and in medulloblastoma where loss of Ink4c collaborates with loss of p53 or Patched but not with loss of Arf (Zindy et al., 2003; Uziel et al., 2005) . Another observation was that Arf deletions were infrequent (1/14) in lymphomas that arose in EmMyc;Ink4c À/À mice when compared to Em-Myc;Ink4c þ / þ cohorts (7/17). It is unclear why Ink4c loss biases against Arf deletions. One possible explanation is that the insertion of the neomycin resistance cassette somehow stabilizes the genomic region encompassing Ink4c and Arf. Alternatively, loss of Ink4c may truly bypass the requirements for Arf deletion, by allowing cells to progress through the cell cycle unchecked. In turn, this could lead to a DNA damage response that bypasses the requirement for Arf loss (Kamijo et al., 1997 (Kamijo et al., , 1999 . These data are in agreement with those showing that p18 Ink4c does not collaborate with Arf loss in medulloblastoma formation (Zindy et al., 2003) . Regardless, future studies are necessary to resolve how p18
Ink4c acts as a cell context-specific tumor suppressor and ultimately how the Rb and Ink4a/Arf networks are differentially wired in cells and tissues.
Materials and methods
Mice and tumor analyses Ink4c
À/À mice on a mixed (129/Sv Â C57BL/6) background (Latres et al., 2000) were bred to Em-Myc transgenic mice on a C57BL/6 background. F1 Em-Myc;Ink4c þ /À offspring were then bred with Ink4c þ /À mice to obtain Ink4c þ / þ , Ink4c þ /À and Ink4c
À/À
; Em-Myc transgenic littermates. Animals were observed daily for tumor development and morbidity. Sick animals were killed, and tumors were collected, flash frozen and stored at À801C.
Cell isolation and culture
Bone marrow and spleen cells were incubated with beads conjugated to a B220 antibody (Miltenyi Biotech, Auburn, CA, USA) and enriched by magnetic separation columns type LS (magnetic-activated cell sorter (MACS), Miltenyi Biotech, Auburn, CA, USA) for B cells.
B-cell proliferation and apoptosis assays
Rates of proliferation of B220 þ /IgM þ and B220 þ /IgM À cells were determined using a Flow kit (BD Biosciences Pharmingen, San Jose, CA, USA). Animals were injected intraperitoneally with 100 ml of 10 mg/ml BrdU in sterile phosphate-buffered saline, killed 12 h post-injection, and bone marrow and spleen were harvested. One million cells were used for BrdU proliferation assays, by incubating cells with antibodies against B220 (allophycocyanin (APC)-conjugated) and IgM (phycoerythrin-conjugated), followed by washes. Labelled cells were further processed and stained with fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody, and analysed by FACS. To determine the apoptotic index, one million cells were incubated with anti-B220, antiIgM and Annexin-V-FITC, and analysed by FACS.
RNA preparation and analyses RNA was prepared from MACS-isolated B cells from 4-to 6-week-old wild-type and Em-Myc littermates, and from tumors p18 Ink4c in Myc-induced transformation LM Nilsson et al or mouse embryonic fibroblasts, using the RNeasy kit (Qiagen, Valencia, CA, USA). With Institutional Review Board approval and after informed consent, RNA (and protein) were also extracted from tumors of 14 Burkitt lymphoma patients using the RNA/DNA kit from Qiagen. For Affymetrix and statistical analyses, see Supplemental Materials and methods.
DNA and array CGH analyses Genomic DNA was prepared from mouse tails or from lymphomas from Em-Myc transgenic mice of various Ink4c genotypes. Thirty micrograms of DNA was digested with EcoRI (for Ink4c Southern blot) or AflII (for Arf Southern blot) and loaded on a 0.8% agarose gels. Following transfer to membranes (Nytran, Scheicher and Schuell, Keene, NH, USA), blots were probed with radio-labelled cDNAs encoding Arf (exon 1b) or Ink4c (Latres et al., 2000) . For array CGH analysis, see Supplemental Materials and methods Snijders et al., 2005) .
